Eubiologics saw the highest growth of 1.99% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Eubiologics’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Eubiologics has been focused on protecting inventions in South Korea(KR) with one publication in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 50% of filings. The South Korea(KR), and United States(US) patent Office are among the top ten patent offices where Eubiologics is filings its patents..
CJ and Sanofi could be the strongest competitors for Eubiologics
Patents related to nanomedicine lead Eubiologics's portfolio
Eubiologics has the highest number of patents in nanomedicine. For nanomedicine, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Respiratory syncytial virus (rsv) infections related patents lead Eubiologics portfolio
Eubiologics has highest number of patents in respiratory syncytial virus (rsv) infections.
For comprehensive analysis of Eubiologics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
